427 related articles for article (PubMed ID: 19021299)
1. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient.
Johnson RW; Wasner G; Saddier P; Baron R
Drugs Aging; 2008; 25(12):991-1006. PubMed ID: 19021299
[TBL] [Abstract][Full Text] [Related]
2. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
Johnson RW
Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
[TBL] [Abstract][Full Text] [Related]
3. Herpes zoster and postherpetic neuralgia.
Johnson RW
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):21-6. PubMed ID: 20192714
[TBL] [Abstract][Full Text] [Related]
4. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
6. Vaccination against Herpes Zoster and Postherpetic Neuralgia.
Oxman MN; Levin MJ;
J Infect Dis; 2008 Mar; 197 Suppl 2(Suppl 2):S228-36. PubMed ID: 18419402
[TBL] [Abstract][Full Text] [Related]
7. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H
Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019
[TBL] [Abstract][Full Text] [Related]
8. The impact of varicella zoster virus: chronic pain.
Opstelten W; McElhaney J; Weinberger B; Oaklander AL; Johnson RW
J Clin Virol; 2010 May; 48 Suppl 1():S8-13. PubMed ID: 20510265
[TBL] [Abstract][Full Text] [Related]
9. Prevention of herpes zoster and its painful and debilitating complications.
Johnson R; McElhaney J; Pedalino B; Levin M
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S43-8. PubMed ID: 18162246
[TBL] [Abstract][Full Text] [Related]
10. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
11. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
[TBL] [Abstract][Full Text] [Related]
12. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A
Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532
[TBL] [Abstract][Full Text] [Related]
14. Increasing incidence associated with herpes zoster infection in British Columbia, Canada.
Marra F; Chong M; Najafzadeh M
BMC Infect Dis; 2016 Oct; 16(1):589. PubMed ID: 27765026
[TBL] [Abstract][Full Text] [Related]
15. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
[TBL] [Abstract][Full Text] [Related]
16. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.
Schmader K; Gnann JW; Watson CP
J Infect Dis; 2008 Mar; 197 Suppl 2():S207-15. PubMed ID: 18419399
[TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
18. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
19. Vaccination against herpes zoster in developed countries: state of the evidence.
Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
[TBL] [Abstract][Full Text] [Related]
20. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
Holcomb K; Weinberg JM
J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
